Viatris Inc.
HealthcareNASDAQ:VTRS · NASDAQ Global Select
+$0.08 today
Vol 6.16M · Avg 10.75M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$14.6B of revenue converted into -$296.5M of net income for the selected period. Gross margin is 34.4% and net margin is -1.9%, showing how much revenue survives after costs and taxes. EPS is $-0.26, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B -3.0% | $14.7B -4.5% | $15.4B -5.1% | $16.3B -9.1% | $17.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.3B +1.9% | $9.1B +1.4% | $9.0B -8.0% | $9.8B -20.7% | $12.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $5.0B -10.8% | $5.6B -12.7% | $6.4B -0.9% | $6.5B +16.5% | $5.6B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 35.1% -3.1pp | 38.2% -3.6pp | 41.7% +1.8pp | 40.0% +8.8pp | 31.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $965.9M +19.4% | $808.7M +0.4% | $805.2M +21.6% | $662.2M -2.8% | $681.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $3.8B -14.3% | $4.4B -4.8% | $4.7B +11.3% | $4.2B -7.7% | $4.5B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $7.7B +36.8% | $5.6B -1.0% | $5.7B +16.2% | $4.9B -13.0% | $5.6B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.8B -3.3% | $2.9B +5.6% | $2.7B -9.5% | $3.0B -32.8% | $4.5B | $374.2M | $1.2B | $631.8M |
| EBITDA | -$395.4M -114.0% | $2.8B -19.8% | $3.5B -45.3% | $6.4B +43.7% | $4.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -2.8% -21.9pp | 19.1% -3.7pp | 22.8% -16.8pp | 39.6% +14.5pp | 25.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$2.7B -26467.3% | $10.1M -98.7% | $766.2M -52.6% | $1.6B +4849.7% | -$34.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -18.6% -18.7pp | 0.1% -4.9pp | 5.0% -5.0pp | 9.9% +10.1pp | -0.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $471.3M -14.3% | $550.0M -4.0% | $573.1M -3.3% | $592.4M -6.9% | $636.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.0B -58.2% | -$633.3M -12.4% | -$563.3M -147.0% | $1.2B +290.1% | -$630.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$3.7B -488.1% | -$623.2M -407.1% | $202.9M -92.8% | $2.8B +523.4% | -$664.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -25.6% -21.4pp | -4.2% -5.5pp | 1.3% -16.0pp | 17.3% +21.0pp | -3.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$150.1M -1464.5% | $11.0M -92.6% | $148.2M -79.8% | $734.6M +21.5% | $604.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$3.5B -454.2% | -$634.2M -1259.4% | $54.7M -97.4% | $2.1B +263.8% | -$1.3B | $4.9B | $4.8B | $4.7B |
| Net Margin | -24.6% -20.3pp | -4.3% -4.7pp | 0.4% -12.4pp | 12.8% +19.9pp | -7.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -466.0% | -$1 -1262.3% | $0 -97.3% | $2 +262.9% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -466.0% | -$1 -1270.0% | $0 -97.4% | $2 +262.9% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.2B -1.9% | $1.2B -0.6% | $1.2B -1.0% | $1.2B +0.3% | $1.2B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.2B -1.9% | $1.2B -1.1% | $1.2B -0.9% | $1.2B +0.7% | $1.2B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.82B
Exact Sciences Corporation
EXAS
$20.03B
Moderna, Inc.
NASDAQ:MRNA
$19.97B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.17B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.17B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.12B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.11B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.11B
Baxter International Inc.
NYSE:BAX
$10.66B
Regencell Bioscience Holdings Limited
NASDAQ:RGC
$9.23B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does VTRS generate?
Viatris Inc. (VTRS) reported $14.30B of revenue in fiscal 2025.
Is VTRS profitable?
Viatris Inc. (VTRS) reported -$3,514,900,000.00 of net income, with a net margin of -24.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.